BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 2827887)

  • 1. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
    Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
    Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.
    Zhang W; Li C; Jin Y; Liu X; Wang Z; Shaw JP; Baguley BC; Wu Z; Liu J
    Drug Deliv; 2018 Nov; 25(1):611-622. PubMed ID: 29493300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.
    Jin Y; Wu Z; Li C; Zhou W; Shaw JP; Baguley BC; Liu J; Zhang W
    Pharm Res; 2018 Jan; 35(1):13. PubMed ID: 29302821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel assay for human tyrosyl DNA phosphodiesterase 2.
    Adhikari S; Karmahapatra SK; Elias H; Dhopeshwarkar P; Williams RS; Byers S; Uren A; Roy R
    Anal Biochem; 2011 Sep; 416(1):112-6. PubMed ID: 21620793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.
    Gurova K
    Future Oncol; 2009 Dec; 5(10):1685-704. PubMed ID: 20001804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA topoisomerase II in cancer chemotherapy.
    Nitiss JL
    Nat Rev Cancer; 2009 May; 9(5):338-50. PubMed ID: 19377506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
    Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
    Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and mode of action of acridine compounds against Leishmania donovani.
    Mesa-Valle CM; Castilla-Calvente J; Sanchez-Moreno M; Moraleda-Lindez V; Barbe J; Osuna A
    Antimicrob Agents Chemother; 1996 Mar; 40(3):684-90. PubMed ID: 8851593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermia, thermotolerance and topoisomerase II inhibitors.
    Kampinga HH
    Br J Cancer; 1995 Aug; 72(2):333-8. PubMed ID: 7640214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro.
    Werbovetz KA; Lehnert EK; Macdonald TL; Pearson RD
    Antimicrob Agents Chemother; 1992 Feb; 36(2):495-7. PubMed ID: 1318684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the DNA breakage and cytotoxic effects of intercalating agents by treatment with sublethal doses of 1-beta-D-arabinofuranosylcytosine or hydroxyurea in L1210 cells.
    Minford J; Kerrigan D; Nichols M; Shackney S; Zwelling LA
    Cancer Res; 1984 Dec; 44(12 Pt 1):5583-93. PubMed ID: 6208999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
    René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
    Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
    Zwelling LA; Silberman L; Estey E
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1041-7. PubMed ID: 2427489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
    Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y
    Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
    Markovits J; Pommier Y; Kerrigan D; Covey JM; Tilchen EJ; Kohn KW
    Cancer Res; 1987 Apr; 47(8):2050-5. PubMed ID: 3030540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of protein-associated DNA breaks by 10-[diethylaminopropylamino]-6-methyl-5H-pyrido[3',4':4,5]pyrrolo [2,3-g]isoquinoline in cultured L1210 cells and in isolated nuclei: comparison with other topoisomerase II inhibitors.
    Pierson V; Pierre A; Pommier Y; Gros P
    Cancer Res; 1988 Mar; 48(6):1404-9. PubMed ID: 2830964
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.